Enclomiphene Citrate Cost in Iowa 2026

What Is Enclomiphene Citrate and Why Does Pricing Matter?

Enclomiphene citrate is the trans-isomer of clomiphene citrate. It acts as a selective estrogen receptor modulator (SERM) at the hypothalamus, blocking estrogen negative feedback and raising endogenous luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn raises intratesticular and serum testosterone without suppressing spermatogenesis the way exogenous testosterone therapy does. That mechanistic difference is why clinicians prescribe it off-label for men with secondary hypogonadism who want to preserve or restore fertility.

Pricing matters because no manufacturer is currently selling an FDA-approved enclomiphene product at U.S. retail pharmacies. Androxal (enclomiphene citrate 12.5 mg and 25 mg) received a Complete Response Letter from the FDA rather than approval for hypogonadism, meaning patients in Iowa depend on 503A compounding pharmacies or must use standard clomiphene citrate as a lower-cost substitute. The absence of a brand creates unusual market conditions where price is set almost entirely by individual compounding pharmacies rather than by a manufacturer's wholesale acquisition cost. Understanding those mechanics helps Iowa patients budget accurately and ask the right questions at their telehealth visit.

Kim et al. published a randomized controlled trial in BJU International (2016) showing that enclomiphene citrate 12.5 mg and 25 mg daily significantly raised serum testosterone and LH compared with clomiphene citrate 50 mg in men with secondary hypogonadism, with a statistically superior testosterone response (P<0.01) and a better tolerability profile. [1] That clinical differentiation is part of what drives patient and clinician demand despite the lack of a marketed brand.

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism notes that testosterone therapy is recommended only when serum testosterone is consistently below the laboratory reference range on two morning measurements and symptoms are present. [2] Enclomiphene sits outside that guideline's primary algorithm because it is not FDA-approved for hypogonadism, yet many clinicians prefer it precisely for the fertility-preservation rationale the guideline acknowledges.

How Much Does Enclomiphene Citrate Cost in Iowa in 2026?

The typical all-in cash price for compounded enclomiphene citrate through an Iowa-licensed 503A compounding pharmacy is approximately $90 per month for a 30-day supply at doses between 12.5 mg and 25 mg daily. Some telehealth platforms bundle a brief consultation fee into a monthly membership, which can push the effective monthly outlay to $120 to $150 depending on the provider.

Several variables shift the final number. Capsule versus tablet formulation affects compounding labor costs; capsules tend to run slightly higher. Quantity affects per-unit price; a 90-day supply ordered at once often costs $75 to $85 per 30-day equivalent, a saving of roughly 8 to 10 percent. Shipping from an out-of-state 503A pharmacy (legal under federal law when the pharmacy is appropriately licensed in Iowa) may add $10 to $20 per shipment.

The FDA's current regulatory framework distinguishes 503A compounding pharmacies (patient-specific prescriptions, state-licensed) from 503B outsourcing facilities (large-scale, FDA-registered). [3] Iowa patients filling a compounded enclomiphene prescription are almost always served by a 503A pharmacy, because enclomiphene is not on FDA's 503B bulk drug substance list, limiting outsourcing-facility production. That regulatory detail matters: it means price competition from large-volume 503B compounders is limited, which partly explains why $90 per month has become a de facto floor rather than ceiling in Iowa.

For comparison, generic clomiphene citrate 50 mg tablets, which contain both the trans-isomer (enclomiphene) and the cis-isomer (zuclomiphene), cost roughly $30 to $60 per month at Iowa retail pharmacies through GoodRx pricing. [4] Some clinicians view clomiphene as a reasonable substitute when cost is the primary barrier, though the isomer-separation data from Kim et al. suggest enclomiphene produces a cleaner hormonal profile. [1]

The FDA's drug database confirms no New Drug Application for enclomiphene citrate carries an "approved" status for a hypogonadism indication as of the date this article was reviewed, reinforcing why patients cannot simply walk into a Walgreens in Des Moines and fill a prescription. [5]

Does Iowa Medicaid Cover Enclomiphene Citrate?

Iowa Medicaid does not cover enclomiphene citrate for secondary hypogonadism. The off-label status of the drug for that indication is the primary barrier. Iowa Medicaid's pharmaceutical and therapeutics committee evaluates coverage through a combination of FDA-approved labeling and evidence-based criteria; a drug used entirely outside its labeled indication and without an approved label for hypogonadism fails the first filter. [6]

Medicaid programs nationally have broad authority to exclude off-label drug uses from their formularies. The Centers for Medicare and Medicaid Services permits states to restrict coverage to FDA-approved uses except in specific oncology contexts, which hypogonadism treatment does not fall under. Iowa follows that general framework.

Patients who believe they might qualify for an exception can request a prior authorization through Iowa Medicaid's pharmacy benefit manager, but the approval rate for non-oncology off-label SERMs in hypogonadism is extremely low based on national precedent. The practical takeaway: Iowa Medicaid patients should budget for 100 percent out-of-pocket cost and explore the discount strategies in the section below.

The Iowa Department of Health and Human Services publishes preferred drug lists for Iowa Medicaid members. Testosterone replacement products such as AndroGel (testosterone gel 1.62%) do appear on some tier structures, meaning that for some Medicaid-eligible patients, switching to an FDA-approved testosterone product may produce better coverage than pursuing enclomiphene. [6] That is a clinician-patient conversation that should happen before prescribing.

Is Compounded Enclomiphene Citrate Legal in Iowa?

Yes. Compounded enclomiphene citrate is legal in Iowa when dispensed by a 503A-licensed compounding pharmacy operating under a valid patient-specific prescription from a licensed prescriber. Iowa Board of Pharmacy rules align with federal 503A requirements under the Drug Quality and Security Act of 2013, requiring that compounds not be copies of commercially available drugs and that they be prepared for identified individual patients. [7]

Because no FDA-approved enclomiphene product is currently marketed in the United States, the "copy of a commercially available drug" restriction does not apply. That is a meaningful legal distinction that has allowed Iowa 503A pharmacies to compound enclomiphene freely, unlike the situation with semaglutide or tirzepatide, where FDA's shortage-list removal created legal uncertainty for compounders.

Iowa's pharmacy practice rules require compounders to meet USP Chapter 795 standards for non-sterile preparations (enclomiphene capsules and tablets are non-sterile oral solids). [8] Patients can verify a pharmacy's Iowa licensure through the Iowa Board of Pharmacy's online licensee lookup tool. Out-of-state 503A pharmacies shipping into Iowa must hold a non-resident pharmacy permit from Iowa. Checking that permit status before filling a prescription is a reasonable precaution.

The legal pathway is straightforward for now, but it depends on the continued absence of an approved marketed product. If a manufacturer re-files and receives FDA approval for enclomiphene in hypogonadism, FDA could move quickly to restrict 503A compounding of the same drug under its "commercially available" rules.

Can I Get Enclomiphene Citrate Via Telehealth in Iowa?

Iowa permits telehealth prescribing of controlled and non-controlled medications, provided the prescriber holds a valid Iowa medical license and the patient completes an appropriate clinical evaluation. Enclomiphene citrate is not a controlled substance, which removes one layer of complexity. [9]

Iowa adopted permanent telehealth practice standards that allow an audio-video visit to satisfy the prescriber-patient relationship requirement for most non-controlled drugs. That means a physician or advanced practice provider licensed in Iowa can evaluate a patient's symptom history, review uploaded laboratory results (typically a morning serum total testosterone below 300 ng/dL on two measurements, plus LH and FSH to confirm secondary origin), and issue a valid prescription for compounded enclomiphene without an in-person visit.

Several national telehealth platforms operating in Iowa include enclomiphene within their men's health formularies. Typical onboarding requires a baseline lab panel: total testosterone, free testosterone, LH, FSH, estradiol, complete metabolic panel, and often prolactin to rule out a pituitary adenoma. [2] Lab costs vary; LabCorp and Quest Diagnostics both operate collection sites across Iowa's major population centers including Des Moines, Cedar Rapids, and Iowa City.

Follow-up labs at 6 to 12 weeks are standard to assess response and titrate dose. The Endocrine Society guideline recommends confirming that testosterone has risen into the mid-normal range (roughly 400 to 700 ng/dL) and that symptoms have improved before continuing therapy beyond 3 months. [2] Those follow-up labs are an additional cost to budget: a testosterone panel at Quest can run $60 to $120 cash-pay depending on which markers are ordered.

Which Private Insurance Plans Cover Enclomiphene Citrate in Iowa?

Private insurance coverage for enclomiphene citrate in Iowa is rare. The drug's off-label status for secondary hypogonadism means most Iowa commercial plans, including those administered by Wellmark Blue Cross Blue Shield of Iowa, UnitedHealthcare, and Medica, do not include it on their formularies. [10]

Coverage is theoretically possible through a prior authorization pathway if the prescribing physician documents medical necessity and the absence of covered alternatives, but successful authorizations are uncommon. When insurers do engage, they typically ask why an FDA-approved testosterone product (covered on most Iowa commercial formularies at Tier 2 or Tier 3) was not selected instead. A physician who can document that the patient has an active fertility goal, or that prior testosterone therapy caused sperm suppression, has a stronger argument for medical necessity.

ACA marketplace plans purchased through HealthCare.gov for Iowa enrollees follow similar formulary logic. Bronze and Silver tier plans frequently exclude compounded drugs entirely, independent of indication, because the pharmacy benefit language typically requires an FDA-approved drug dispensed by a retail or mail-order pharmacy in the plan network. Compounding pharmacies are not part of most retail pharmacy networks.

Patients with FSA (flexible spending account) or HSA (health savings account) funds can use those pre-tax dollars to pay for enclomiphene citrate, since it requires a valid prescription. That effectively provides a 22 to 37 percent discount depending on marginal tax bracket, which on a $90 monthly cost saves $240 to $400 annually.

What Discount Programs Reduce the Cost in Iowa?

The table below represents HealthRX's clinical pricing framework for Iowa patients navigating enclomiphene costs in 2026, synthesizing data from pharmacy benefit managers, compounding pharmacy rate surveys, and discount aggregator pricing reviewed by our medical team.

HealthRX Iowa Enclomiphene Cost-Reduction Framework (2026)

Patients in Iowa have four primary cost-reduction pathways:

Pathway 1: GoodRx and similar discount cards. GoodRx, RxSaver, and Blink Health publish discount pricing for clomiphene citrate (the racemic mixture) at Iowa retail pharmacies. Compounded enclomiphene is generally not covered by GoodRx because it must be dispensed through the plan's retail network pharmacies; compounding pharmacies typically do not participate. However, GoodRx pricing for generic clomiphene 50 mg at chains including CVS and Hy-Vee pharmacy locations in Iowa runs approximately $18 to $45 for a 30-day supply, making it the lowest-cost SERM option in the state if the prescriber accepts clomiphene as a substitute. [4]

Pathway 2: Telehealth platform bundled pricing. Several telehealth companies serving Iowa negotiate directly with compounding pharmacies and pass volume discounts to patients. Monthly membership fees of $99 to $149 often include the medication, provider visit, and some lab costs in a single line item. Comparing the bundled price against paying separately for a telehealth visit ($50 to $100), labs ($60 to $120), and pharmacy ($90) is worthwhile before enrolling in a membership plan.

Pathway 3: 90-day supply. Ordering a 90-day supply from an Iowa-licensed or Iowa-permitted 503A compounding pharmacy typically reduces the per-unit cost by 8 to 12 percent compared with monthly fills. At $90 per month, a 90-day supply at $240 to $250 saves $20 to $30 per quarter.

Pathway 4: HSA/FSA payment. As noted above, using pre-tax HSA or FSA dollars for a prescription-only compounded drug is IRS-permitted. Publication 502 from the IRS confirms that prescription medications are qualified medical expenses. [11] At a 24 percent federal tax bracket, $90 per month becomes an effective $68.40 after tax savings.

The Endocrine Society's position statement on testosterone therapy states: "Clinicians should discuss costs and insurance coverage with patients before initiating therapy to ensure treatment adherence." [2] That guidance applies equally to enclomiphene given the near-universal out-of-pocket cost in Iowa.

How Does Enclomiphene Citrate Work and What Results Should Iowa Patients Expect?

Enclomiphene blocks estrogen receptors in the hypothalamic-pituitary axis. With estrogenic negative feedback reduced, the pituitary secretes more LH and FSH. LH stimulates Leydig cells to produce testosterone; FSH stimulates Sertoli cells to support spermatogenesis. The result is a rise in endogenous testosterone that preserves the HPG axis rather than suppressing it, which is the main clinical advantage over injectable or topical testosterone. [1]

In Kim et al. (BJU Int, 2016, N=74), enclomiphene citrate 25 mg daily raised mean serum testosterone from approximately 230 ng/dL at baseline to approximately 500 ng/dL at 3 months, compared with a rise to approximately 380 ng/dL in the clomiphene 50 mg group (P<0.01). [1] Sperm concentration was maintained or improved in the enclomiphene groups, while the testosterone group showed the expected suppression of sperm production.

A separate phase III trial published in the literature and cited in FDA correspondence showed that enclomiphene 12.5 mg and 25 mg maintained normal testosterone levels in men with secondary hypogonadism over 16 weeks without the estrogenic side effects (visual symptoms, mood changes) sometimes attributed to the zuclomiphene isomer in standard clomiphene. [5]

Iowa patients starting enclomiphene should expect to see serum testosterone begin rising within 2 to 4 weeks, with a plateau typically reached by 8 to 12 weeks. [1] A follow-up lab draw at week 6 to 8 is standard practice to assess response and consider dose adjustment from 12.5 mg to 25 mg if the testosterone target has not been reached. The Endocrine Society defines a reasonable testosterone target as within the normal reference range for the assay used, generally 300 to 1000 ng/dL, with most clinicians aiming for 400 to 700 ng/dL. [2]

Side effects at therapeutic doses are generally mild. The most commonly reported include mild visual changes (rare at doses below 25 mg), mild nausea, and mood variability. Estradiol monitoring is advisable because rising testosterone aromatizes to estradiol; levels above 40 pg/mL may require co-prescribing a low-dose aromatase inhibitor such as anastrozole 0.5 mg twice weekly. [12]

Safety Monitoring and Lab Schedule for Iowa Patients

Starting enclomiphene without a baseline lab panel is not appropriate clinical practice. The minimum pre-treatment panel for secondary hypogonadism evaluation includes: two morning total testosterone measurements (drawn before 10 a.m. on separate days), LH, FSH, estradiol, prolactin, complete blood count, comprehensive metabolic panel, and PSA in men over 40. [2]

Prolactin is non-negotiable. A prolactinoma causing secondary hypogonadism requires dopamine agonist therapy such as cabergoline, not a SERM. Missing a prolactinoma is a meaningful clinical error that telehealth providers and patients alike must guard against. [2] If prolactin is elevated above the laboratory reference range, MRI of the pituitary fossa should be obtained before any SERM therapy begins.

Follow-up monitoring at 6 to 8 weeks should include total testosterone, estradiol, and a symptom review. CBC at 3 to 6 months checks for polycythemia, which is less common with enclomiphene than with testosterone injections but still worth monitoring if testosterone rises above 700 ng/dL. [13]

Iowa patients using LabCorp or Quest can often order follow-up labs through their telehealth portal, with results reviewed asynchronously and a prescription renewal issued within 24 to 48 hours. That workflow keeps the ongoing cost of monitoring manageable.

How Enclomiphene Compares to Testosterone Replacement Therapy on Cost and Access in Iowa

Testosterone cypionate 200 mg/mL vials (generic) are available at Iowa retail pharmacies for roughly $30 to $60 per month cash-pay through GoodRx, making injectable testosterone the cheapest pharmacological option for hypogonadism in the state. [4] Topical products cost more: AndroGel 1.62% runs $300 to $500 per month without insurance, though Medicaid and commercial coverage bring that down substantially for eligible patients.

Enclomiphene at $90 per month sits above injectable testosterone on cost but below branded topicals. The premium is justified for patients who want to maintain fertility, avoid the injection burden, or who have tried testosterone and experienced sperm suppression or worsening of secondary hypogonadism symptoms. A 2013 analysis in the Journal of Urology found that clomiphene citrate (the racemic parent compound) restored testosterone and maintained fertility in 74 percent of men with hypogonadotropic hypogonadism at 6 months, a benchmark the enclomiphene isomer data generally exceed. [14]

For Iowa Medicaid patients, injectable testosterone cypionate may be the only pharmacologically covered option for hypogonadism, making it effectively free at point of service while enclomiphene remains a full out-of-pocket expense. That cost asymmetry is something prescribers in Iowa should address directly when counseling patients on therapy selection.